Enjeux de la prise en charge du virus de l’hépatite B (VHB) en transplantation

Autor:	Fabien Zoulim, Clothilde Miaglia, Fanny Lebossé
Rok vydání:	2018
Předmět:	Hepatitis B virus biology business.industry medicine.medical_treatment virus diseases Hematopoietic stem cell transplantation Liver transplantation medicine.disease_cause medicine.disease Virology digestive system diseases Transplantation Infectious Diseases Viral replication Hepatocellular carcinoma biology.protein medicine Antibody business Fulminant hepatitis
Zdroj:	Virologie. 22:277-288
ISSN:	1950-6961 1267-8694
DOI:	10.1684/vir.2018.0755
Popis:	Clinical manifestations of hepatitis B virus (HBV) infection are ranged from fulminant hepatitis to decompensated cirrhosis or hepatocellular carcinoma. Liver transplantation (LT) is one therapeutic option of these HBV infection complications. Intrahepatic viral persistence and low levels of circulating viral particles despite treatment optimization may lead to HBV recurrence after LT, which jeopardizes graft and patients survival after LT. HBV recurrence prophylactic strategies are based on nucleos(t)ides analogues (NUCs) treatment to block viral replication and anti-HBs immunoglobulin administration to neutralize circulating viral particles. The risk of HBV recurrence is also important in case of transplantation with a graft from a donor with a history of HBV infection (HBc+) to a "HBV naive" recipient or in case of immunosuppressive therapy after solid organ or hematopoietic stem cell transplantation for a HBc+ recipient. Prophylactic strategies are mainly focused on biological monitoring and NUCs therapy for high-risk situations.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::471731bd96f2ed0e813748ec535edcb9 https://doi.org/10.1684/vir.2018.0755 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.